

PRESS NEWS

Gradientech Announces Prominent International Scientific Advisory Board: Prof. G. Kahlmeter, Assoc. Prof. J. Bender and Prof. H. Rhode

Uppsala, December 15, 2020. Swedish diagnostics firm Gradientech is proud to announce the appointment of three internationally renowned members to the company's scientific advisory board, SAB. With their expertise in clinical microbiology, the new advisors will provide valuable support in preparing for a successful market launch of Gradientech's *in vitro* diagnostic system for ultra-rapid antibiotic susceptibility testing, claimed to be the fastest among new systems in development.

"To significantly shorten the time to an AST result is of tremendous importance to the patient and the clinical colleague in charge! Anything that we can do to help speed up testing without compromising quality and safety is worth our efforts", says Gunnar Kahlmeter, member of the SAB.

"All members of our new SAB have been in Gradientech's advisory network for several years, but we are now formalising the collaboration further to intensify the work and gather the collected knowledge in one place. It is a true honour to work with such experienced advisors", says Sara Thorslund, CEO of Gradientech.

Prof. Gunnar Kahlmeter is a leading authority in the field of antibiotic resistance and antimicrobial susceptibility testing. Gunnar Kahlmeter chaired the European Committee on Antimicrobial Susceptibility Testing, EUCAST, for more than a decade. He is former president of the European Society of Clinical Microbiology and Infectious Diseases, ESCMID, and currently leads the EUCAST Development Laboratory and National Reference Laboratory on phenotypic susceptibility testing, based at the Central Hospital in Växjö, Sweden, where he also headed the Dep of Clinical Microbiology for over 30 years.

Assoc. Prof. Jeffrey Bender is an Infection Disease Physician and Medical Microbiologist at the Children's Hospital Los Angeles, CA, USA. Jeffrey Bender works clinically with treating children suffering sepsis and has a special interest and experience in the implementation of rapid antibiotic susceptibility testing (AST) diagnostics in the paediatric setting.

Prof. Holger Rhode is a senior physician and deputy head of the Institute for Medical Microbiology, Virology and Hygiene at the Universitätsklinikum Hamburg-Eppendorf, UKE, Germany. Holger Rhode is an advocate of rapid AST diagnostics and has ample experience validating new and innovative technologies.

*Gradientech is a Swedish diagnostics company developing the *in vitro* diagnostic QuickMIC® system, a new innovative platform based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining the appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital to increase sepsis patient survival, reduce healthcare costs and lower the spread of antibiotic resistance. www.gradientech.se*

For further information, please contact:

Sara Thorslund, PhD, CEO Gradientech

Tel: +46 736 29 35 80, email: sara.thorslund@gradientech.se